• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Drug-delivery tech developer AMW lands $30m from EU bank

January 4, 2018 By Sarah Faulkner

AMWDrug-delivery tech developer AMW has landed $30 million from the European Union’s lending institution to help fund the company’s development activities and expand production capacity.

The German pharmaceutical company’s newly-acquired funds will specifically support a new R&D facility located in Bavaria.

The transaction was supported by the European Fund for Strategic Investments.

“Supporting research, development and innovation with an important health impact is a key priority for the European Investment Bank. Our transaction with AMW, supported by EFSI, is a perfect demonstration of the real, tangible benefits that Europe is providing in supporting young innovative pharma companies and promoting sustainable growth and jobs,” Ambriose Fayolle, VP of the EIB for innovation, EFSI and Germany, said in prepared remarks.

“This is our first transaction with AMW. I am delighted that we can, in particular through our long tenor, support an innovative company active in an area that makes a real difference in people’s daily lives.”

“AMW has an increasing pipeline of advanced-stage R&D projects close to market entry generating additional financing needs. We have been looking for an R&D-focused type of financing for quite some time, and believe that this dedicated programme is a perfect match for sustaining our growth rate by addressing the unmet needs of patients with severe diseases,” AMW’s founder & managing director, Wilfried Fischer, added.

“With the acceleration of the R&D projects, we are confident of our ability to act as a major player in new drug delivery systems in multi-billion euro target markets like diabetes or breast cancer – based and growing in the European Union. Speed is key for pharmaceutical markets and together with the EIB we are able to enter the next stage of our company’s growth.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Research & Development Tagged With: amw

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS